Quest Diagnostics Inc (NYSE:DGX) – Stock analysts at William Blair raised their Q2 2019 earnings estimates for shares of Quest Diagnostics in a research note issued to investors on Tuesday. William Blair analyst A. Murphy now expects that the medical research company will earn $1.83 per share for the quarter, up from their prior forecast of $1.59. William Blair also issued estimates for Quest Diagnostics’ Q3 2019 earnings at $1.76 EPS, Q4 2019 earnings at $1.69 EPS and FY2020 earnings at $7.14 EPS.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, February 1st. The medical research company reported $1.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.03. Quest Diagnostics had a return on equity of 15.41% and a net margin of 10.00%. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same period in the prior year, the business posted $1.31 earnings per share. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year.

A number of other research firms have also recently weighed in on DGX. Zacks Investment Research cut shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, October 27th. Mizuho set a $103.00 price target on shares of Quest Diagnostics and gave the company a “buy” rating in a research report on Thursday, October 19th. Canaccord Genuity increased their price target on shares of Quest Diagnostics from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, October 26th. Evercore ISI started coverage on shares of Quest Diagnostics in a research report on Thursday, January 4th. They set an “in-line” rating and a $103.00 price target for the company. Finally, SunTrust Banks set a $105.00 price target on shares of Quest Diagnostics and gave the company a “hold” rating in a research report on Sunday, October 15th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $107.40.

Shares of Quest Diagnostics (NYSE:DGX) traded up $0.12 during trading hours on Wednesday, reaching $101.25. The company’s stock had a trading volume of 633,504 shares, compared to its average volume of 993,553. The firm has a market capitalization of $13,880.00, a price-to-earnings ratio of 18.51, a PEG ratio of 1.82 and a beta of 0.67. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.24 and a quick ratio of 1.15. Quest Diagnostics has a 12 month low of $90.10 and a 12 month high of $112.96.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 18th. Stockholders of record on Wednesday, April 4th will be issued a dividend of $0.50 per share. The ex-dividend date is Tuesday, April 3rd. This represents a $2.00 annualized dividend and a dividend yield of 1.98%. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.45. Quest Diagnostics’s dividend payout ratio is 32.73%.

In related news, SVP Catherine T. Doherty sold 21,294 shares of the stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $104.00, for a total value of $2,214,576.00. Following the transaction, the senior vice president now owns 90,709 shares in the company, valued at approximately $9,433,736. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP J. E. Davis sold 63,880 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $98.68, for a total transaction of $6,303,678.40. Following the completion of the transaction, the executive vice president now owns 101,423 shares in the company, valued at approximately $10,008,421.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 192,014 shares of company stock worth $19,950,134. Corporate insiders own 1.75% of the company’s stock.

A number of large investors have recently modified their holdings of DGX. Thrivent Financial For Lutherans grew its stake in shares of Quest Diagnostics by 2.0% during the 2nd quarter. Thrivent Financial For Lutherans now owns 5,200 shares of the medical research company’s stock worth $578,000 after purchasing an additional 100 shares during the period. QS Investors LLC lifted its stake in Quest Diagnostics by 5.7% in the second quarter. QS Investors LLC now owns 10,551 shares of the medical research company’s stock valued at $1,173,000 after buying an additional 568 shares during the last quarter. HighTower Advisors LLC lifted its stake in Quest Diagnostics by 9.8% in the second quarter. HighTower Advisors LLC now owns 13,513 shares of the medical research company’s stock valued at $1,505,000 after buying an additional 1,201 shares during the last quarter. Royal Bank of Canada lifted its stake in Quest Diagnostics by 10.5% in the second quarter. Royal Bank of Canada now owns 71,645 shares of the medical research company’s stock valued at $7,967,000 after buying an additional 6,820 shares during the last quarter. Finally, BlueCrest Capital Management Ltd lifted its stake in Quest Diagnostics by 38.9% in the second quarter. BlueCrest Capital Management Ltd now owns 3,048 shares of the medical research company’s stock valued at $339,000 after buying an additional 853 shares during the last quarter. Institutional investors own 89.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/07/quest-diagnostics-inc-to-post-q2-2019-earnings-of-1-83-per-share-william-blair-forecasts-dgx.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.